
Jubilant Therapeutics Presents Phase 1 Data for JBI-802
Jubilant Therapeutics announced the oral presentation of preliminary Phase 1 clinical data for JBI-802, a first-in-class oral dual LSD1/HDAC6 inhibitor, at the 68th ASH Annual Meeting. The data from the ongoing Phase 1/2 study in Essential Thrombocythemia and related Myeloproliferative Neoplasms showed encouraging early evidence of rapid platelet reductions and hematologic control. Specifically, all 8 patients treated at 15 mg achieved over 50% platelet reduction or normalization by Week 3, with a median response time of 15 days. Platelet normalization was sustained in patients with over 12 weeks of follow-up. No dose-limiting toxicities were observed. Jubilant will host a corporate event on December 14, 2026, to discuss the clinical implications of these findings.
Key Highlights
- Preliminary Phase 1 data for JBI-802 presented at ASH meeting.
- JBI-802 showed rapid platelet reduction and hematologic control.
- No dose-limiting toxicities observed in Phase 1 study.
- Company to host event on December 14 to discuss data.
Price Impact
More from JUBLPHARMA
More in Clinical Trial